Nexus NeuroTech Ventures

Nexus NeuroTech Ventures is a venture capital firm founded in 2023, committed to advancing breakthrough technologies for brain disorders. The firm focuses on investing in companies developing innovative solutions for neurodegenerative, neuropsychiatric, and neurodevelopmental disorders, including Parkinson’s disease, bipolar disorder, and autism spectrum disorder. Their investment approach spans a range of technologies, from less invasive to more invasive medical treatments, software and hardware-based diagnostic tools, data platforms supporting clinical trials and care, and tools aimed at advancing therapy development and optimizing clinical care.

The firm's investment strategy targets companies with compelling technology and promising initial human data, enabling their successful technological and business development, as well as clinical evidence generation and market access. Nexus NeuroTech Ventures also offers an incubator program to nurture promising neurotechnology initiatives that require additional technical refinement, preliminary clinical evidence generation, and guidance before they are prepared for conventional venture capital backing.

The team at Nexus NeuroTech Ventures brings together leaders in neurotechnology, clinical neuroscience, and biomedical engineering, including co-founders Dr. Jordi Parramon and Dr. William Marks. Their combined expertise allows the firm to identify and accelerate technology solutions that address patients’ needs along their journeys, aiming to bring impactful solutions to people affected by neurological disorders or psychiatric conditions.